BJU Int. 2020 Aug 17. doi: 10.1111/bju.15214. Online ahead of print.
We read with interest the article by Mostafid et al.(1) devoted to assessing the curative effects of chemoablation with endovescical mitomycin-C versus surgical management in low risk non-muscle invasive bladder cancer (defined as European Organisation for Research and Treatment of Cancer [EORTC] risk of recurrence score ≤6) with visual diagnosis of recurrence and no previous history of non-urothelial bladder cancer or high grade /≥T1 disease.